PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	175-208	phosphopantothenoylcysteine synthetase	Homo sapiens	50-84
31707730-1	2020	2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) is an experimental therapy for Niemann-Pick disease type C (NPC) that reduced neuronal cholesterol and ganglioside storage, reduced Purkinje cell death, and increased lifespan in npc1-/- mice and NPC1 cats.	2-hydroxypropyl-beta-cyclodextrin	0-33	beta-carotene oxygenase 1	Mus musculus	38-45
31707730-1	2020	2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) is an experimental therapy for Niemann-Pick disease type C (NPC) that reduced neuronal cholesterol and ganglioside storage, reduced Purkinje cell death, and increased lifespan in npc1-/- mice and NPC1 cats.	2-hydroxypropyl-beta-cyclodextrin	0-33	NPC intracellular cholesterol transporter 1	Mus musculus	226-230
31707730-1	2020	2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) is an experimental therapy for Niemann-Pick disease type C (NPC) that reduced neuronal cholesterol and ganglioside storage, reduced Purkinje cell death, and increased lifespan in npc1-/- mice and NPC1 cats.	2-hydroxypropyl-beta-cyclodextrin	0-33	NPC intracellular cholesterol transporter 1	Mus musculus	243-247
32070761-0	2020	Drug-in-hydroxypropyl-beta-cyclodextrin-in-lipoid S100/cholesterol liposomes: effect of the characteristics of essential oil components on their encapsulation and release.	2-hydroxypropyl-beta-cyclodextrin	8-39	S100 calcium binding protein B	Homo sapiens	50-54
32070761-3	2020	Hydroxypropyl-beta-cyclodextrin/EO component (HP-beta-CD/EO component) inclusion complexes were prepared in aqueous solution and loaded into liposomes by the ethanol injection method.	2-hydroxypropyl-beta-cyclodextrin	0-31	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	49-56
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	175-208	phosphopantothenoylcysteine synthetase	Homo sapiens	86-90
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	210-218	phosphopantothenoylcysteine synthetase	Homo sapiens	50-84
32033912-3	2020	The most abundant species in this class of lipid, N-palmitoyl-O-phosphocholineserine (PPCS), was evaluated for diagnosis of NPC disease and treatment efficacy assessment with 2-hydroxypropyl-beta-cyclodextrin (HPbetaCD) in NPC.	2-hydroxypropyl-beta-cyclodextrin	210-218	phosphopantothenoylcysteine synthetase	Homo sapiens	86-90
32033912-8	2020	In an intravenous (IV) HPbetaCD trial, plasma PPCS in all patients was significantly reduced.	2-hydroxypropyl-beta-cyclodextrin	23-31	phosphopantothenoylcysteine synthetase	Homo sapiens	46-50
32033912-9	2020	These results demonstrate that plasma PPCS was able to diagnose NPC1 patients with high sensitivity and specificity, and to evaluate the peripheral treatment efficacy of IV HPbetaCD treatment.	2-hydroxypropyl-beta-cyclodextrin	173-181	phosphopantothenoylcysteine synthetase	Homo sapiens	38-42
32019132-0	2020	Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in Npc1-Null Cells.	2-hydroxypropyl-beta-cyclodextrin	24-53	NPC intracellular cholesterol transporter 1	Cricetulus griseus	79-83
32019132-2	2020	The iminosugar miglustat, which inhibits hexosylceramide synthesis, is used for NPC treatment, and 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD), a cyclic oligosaccharide derivative, is being developed to treat NPC.	2-hydroxypropyl-beta-cyclodextrin	99-132	adrenocortical dysplasia protein homolog	Cricetulus griseus	137-144
32019132-5	2020	HP-beta-CD and HP-gamma-CD, unlike HP-alpha-CD, reduced intracellular free cholesterol levels and normalized the lysosome changes in Npc1-null cells but not in wild-type CHO cells.	2-hydroxypropyl-beta-cyclodextrin	15-26	NPC intracellular cholesterol transporter 1	Cricetulus griseus	133-137
32019132-8	2020	Interestingly, HP-beta-CD and HP-gamma-CD, unlike HP-alpha-CD, reduced sphingomyelins in Npc1-null, but not wild-type, cells.	2-hydroxypropyl-beta-cyclodextrin	30-41	NPC intracellular cholesterol transporter 1	Cricetulus griseus	89-93
31700700-5	2019	We found that animals treated using a combination of VEGF and CD showed an improvement in pathophysiology compared to those treated with CD alone or brain VEGF overexpression alone, or non-treated NP-C mice.	2-hydroxypropyl-beta-cyclodextrin	137-139	vascular endothelial growth factor A	Mus musculus	53-57
31790691-0	2020	Naringenin complexed with hydroxypropyl-beta-cyclodextrin improves the sciatic nerve regeneration through inhibition of p75NTR and JNK pathway.	2-hydroxypropyl-beta-cyclodextrin	26-57	nerve growth factor receptor (TNFR superfamily, member 16)	Mus musculus	120-126
31790691-0	2020	Naringenin complexed with hydroxypropyl-beta-cyclodextrin improves the sciatic nerve regeneration through inhibition of p75NTR and JNK pathway.	2-hydroxypropyl-beta-cyclodextrin	26-57	mitogen-activated protein kinase 8	Mus musculus	131-134